OpenAI and Anthropic Make Two Very Different Acquisitions

OpenAI and Anthropic Make Two Very Different Acquisitions

---

1. Key Themes

AI Labs Are Acquiring in Opposite Directions: Distribution vs. Deep Science

OpenAI's purchase of TBPN — a tech talk show with ~70,000 viewers and ~$5M in ad revenue — signals a bet that audience and distribution are strategic moats worth owning. Meanwhile, Anthropic paid $400M+ for Coefficient Bio, an eight-month-old stealth AI biology startup, signaling a deeper conviction in applied science and vertical AI.

"OpenAI has acquired TBPN, an 18-month-old tech talk show and interview platform with an audience of approximately 70,000 viewers that generated about $5 million in ad revenue last year."

"Anthropic just acquired Coefficient Bio, an eight-month-old stealth startup building AI models for biological research, in a stock deal worth just over $400 million."

---

AI-Native Businesses Are Collapsing the Headcount-to-Revenue Ratio

Medvi is the extreme case study: approaching $2B in annual revenue with just two employees. This is a signal, not an outlier — it points to a structural shift in what "company scale" means in an AI-native era.

"Medvi, a Los Angeles-based telehealth seller of GLP-1 weight-loss drugs, says it generated $401 million in 2025 sales and is on track for $1.8 billion this year with just two employees, relying heavily on AI tools to handle everything from coding and marketing to customer service."

---

Silicon Valley Is Taking Over Deep Space — Government Stepping Back

NASA's Artemis II marks a historical turning point: the last major deep space mission built primarily on government infrastructure. Future lunar and deep space missions will be commercially led by venture-backed companies.

"This is likely the last time NASA will try to send people to deep space without major assistance from a company that emerged from the venture-backed tech scene."

"Next time around, however, the pressure will be on SpaceX or Jeff Bezos' Blue Origin. The two companies are competing to see who will put boots on the lunar regolith."

---

Enterprise Identity Security Is a Growing Investment Theme

Two separate $50M Series B rounds in the same newsletter cycle — Alcatraz (physical identity/facial authentication) and Linx Security (human and machine identity governance) — suggest enterprise identity infrastructure is drawing serious capital.

"Alcatraz...secures building entry points with facial authentication that verifies employees without storing their images, raised a $50 million Series B round."

"Linx Security...monitors and governs human and machine identities across enterprise systems, raised a $50 million Series B round."

---

Crypto Infrastructure Is Maturing Into Regulated Financial Services

Coinbase winning conditional approval for a national trust company charter is a meaningful step toward crypto becoming part of the regulated financial backbone — not just a trading venue.

"Coinbase says it has won conditional approval for a national trust company charter, a move that could expand its custody business and eventually open the door to offerings like stablecoins and tokenized securities."

---

2. Contrarian Perspectives

Media and Distribution Are Worth More Than Small Revenue Numbers Suggest

OpenAI paying a meaningful acquisition price for a platform doing only $5M in revenue seems irrational by traditional valuation standards. The contrarian read: at scale, owning the narrative infrastructure and developer mindshare may be more valuable than the financials imply. AI labs may increasingly compete on cultural presence, not just model benchmarks.

"OpenAI has acquired TBPN, an 18-month-old tech talk show and interview platform with an audience of approximately 70,000 viewers that generated about $5 million in ad revenue last year."

---

FDA Clearance Is a Real and Underestimated Moat for AI Health Startups

Kintsugi's shutdown — after seven years of development — despite building seemingly compelling technology (AI that detects depression and anxiety from speech) is a cautionary data point. The FDA pathway is not merely a compliance checkbox; it's a genuine company-killing risk that investors may systematically underprice.

"Kintsugi, a seven-year-old Berkeley startup that built AI to detect depression and anxiety from speech patterns, is shutting down after failing to secure FDA clearance and will open-source most of its technology."

---

High-Profile AI Startups Are More Fragile Than Their Valuations Suggest

Poolside — which had a $2B funding round anchored by Nvidia — is now scrambling for data center partners after both its CoreWeave deal and funding round collapsed. Big-name backers and large headline rounds do not insulate companies from fundamental infrastructure and capital risk.

"Poolside, the high-profile, three-year-old San Francisco startup building coding-focused AI for government and defense customers, is seeking new data center partners after a deal with CoreWeave collapsed and a $2 billion funding round anchored by Nvidia fell apart."

---

3. Companies Identified

---

4. People Identified

---

5. Operating Insights

AI Tools Can Now Functionally Replace Entire Operating Teams

Medvi is the clearest proof point to date. Founders should audit which functions in their business can be AI-first rather than human-first — not as a cost-cutting measure, but as a growth architecture decision. The question is no longer "where can AI assist?" but "where do we actually need humans?"

"Relying heavily on AI tools to handle everything from coding and marketing to customer service."

---

Acquiring Distribution May Be as Valuable as Acquiring Technology

OpenAI's TBPN acquisition suggests that for AI companies, the battle for developer and consumer mindshare is being fought on media terrain. Operators building in crowded AI categories should consider owned-media and community as a core part of their go-to-market stack — not a nice-to-have.

"OpenAI has acquired TBPN, an 18-month-old tech talk show and interview platform with an audience of approximately 70,000 viewers."

---

FDA Strategy Must Be Resourced Like a Core Product Risk, Not an Afterthought

Kintsugi's shutdown after seven years demonstrates that technical excellence is insufficient in regulated health AI. Teams building in clinical or diagnostic AI must treat regulatory pathway as a primary design constraint from day one.

"Kintsugi...is shutting down after failing to secure FDA clearance and will open-source most of its technology."

---

6. Overlooked Insights

Secondary Markets for Private Startup Shares Are Getting Infrastructure Investment

Earlyasset, a one-year-old startup building a platform for secondary sales of private startup shares, raised a $2M pre-seed. This is a small round, but the category is significant — as liquidity timelines for VC-backed companies stretch longer, secondary infrastructure becomes increasingly important for founders, employees, and early investors seeking exits.

"Earlyasset...aims to build a platform for secondary sales of private startup shares, raised a $2 million pre-seed round."

---

Midwest-Focused Venture Capital Is Quietly Institutionalizing

Gateway Capital, a Milwaukee-based VC firm focused on supply chain, logistics, and manufacturing AI, announced the first close of its second fund. This is a small signal but consistent with a broader pattern of non-coastal capital formation targeting industrial AI — a category that coastal VCs have historically underfunded.

"Gateway Capital, a six-year-old Milwaukee VC firm that invests across sectors with a bias toward Midwest industries like supply chain, logistics, and manufacturing AI, has announced the first close of its $25 million second fund."